Medical/Pharmaceuticals

Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

ROME, March 11, 2026 /PRNewswire/ -- Haier Biomedical recently convened its European Partner Summit in Rome under the theme "Advancing Together - Sharing the Future of Biomedical Innovation," which brought together 37 regional partners and industry leaders fro...

2026-03-11 12:29 6727

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer

SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical Development Department, Production Department an...

2026-03-11 09:38 5060

Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements

BEIJING, March 10, 2026 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. (" Tsingke Biotech ") and iGeneTech Bioscience Co., Ltd. ("iGeneTech") have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together th...

2026-03-10 22:13 5696

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...

2026-03-10 21:02 6953

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...

2026-03-10 18:40 6126

Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity

-    ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. -    ASC30 SQ depot formulation maintained weight loss for the four months following the third and final mon...

2026-03-10 18:00 7803

K-pop Singer and Actress Kim Sejeong Named Global Brand Ambassador for 'REJURAN' and 'REJURAN COSMETICS'

GANGNEUNG, South Korea, March 10, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO Jihoon Sohn) announced that singer and actress Kim Sejeong has been named the new global brand ambassador for its flagship brands REJURAN® and REJURAN® COSMETICS.

2026-03-10 16:03 6590

Clarivate Expands Access to Trusted Regulatory Intelligence Within Claude

Advancing Clarivate strategy to extend proprietary intelligence into enterprise AI ecosystems Bringing Clarivate domain-specific regulatory insights into Claude to support life sciences workflows LONDON, March 10, 2026 /PRNewswire/ -- Clarivate Plc

2026-03-10 16:00 6175

The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

HOUSTON, March 10, 2026 /PRNewswire/ -- While exotoxins dominate discussions of bacterial infections, endotoxins—cell wall components released upon bacterial death—are equally dangerous. These endotoxins trigger hyperinflammatory responses that spiral into endotoxemia, in which bloodstream endoto...

2026-03-10 15:22 4334

Robot anxiety is highest where robots are least visible, new global study from Hexagon finds

* A global split in confidence: UK adults are most anxious (52%) vs South Korea least (29%), while high-exposure markets like China (75% of adults have seen/used robots) are also the most excited about robots' potential (81%) * The biggest concern is security, not jobs: Hacking is the top conc...

2026-03-10 15:00 4420

Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics

HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a global leader in in advanced brain health diagnostics. The partnership will introduce the Precivit...

2026-03-10 09:33 5575

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

* Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link:https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia...

2026-03-10 06:34 5228

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (...

2026-03-09 21:27 9055

Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed

News Summary: * Reduces standard testing times by 80%.1 * Delivers an industry-leading 25,000 data points per second, detecting transient material behaviors previously invisible to measurement. 2 * Operates with fewer calibrations and superior atmosphere and temperature control. 3 SAN ANTON...

2026-03-09 21:04 4625

Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers

ST. LOUIS, March 9, 2026 /PRNewswire/ -- Seeger Weiss LLP, Motley Rice LLC, Waters Kraus Paul & Siegel, Williams Hart & Boundas LLP, The Holland Law Firm, and Ketchmark & McCreight P.C. announce that the Circuit Court of the City of St. Louis, State of Missouri, has granted preliminary approval o...

2026-03-09 20:00 5287

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug ...

2026-03-09 19:39 5845

IgHM - A New Breakthrough in Immunonutrition

HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ -- With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin - a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex...

2026-03-09 19:13 3971

G-NiiB GenieBiome and Ocean Park Conclude Gut Microbiome Education Programme

Two–Year Initiative Reaches Over 200,000 Parents and Children Student Artworks Reflect Early Understanding of Gut Health HONG KONG, March 9, 2026 /PRNewswire/ -- The gut is responsible for more than digestion and is often described as the body's "second brain." Research in recent years has highli...

2026-03-09 17:10 4594

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...

2026-03-09 16:32 6344

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...

2026-03-09 14:28 5981
1 ... 40414243444546 ... 649